更新于：2024-11-01

University Hospital of Brest

France

更新于：2024-11-01

概览

概览

关联

571

项与 University Hospital of Brest 相关的临床试验

NCT06627153 / Not yet recruitingN/AIIT

Epidemiological Assessment of Technical Diving Accidents in Mainland France and Factors Predictive of Severity

This retrospective study aims at an epidemiological description of the clinical presentation of medical problems in technical diving. It assess anthropometric data, diving experience and dive planification, clinical presentation, treatment received and pronostic to understand specificity of this community.

开始日期2025-01-01

申办/合作机构

University Hospital of Brest

NCT06435299 / Not yet recruiting临床3期IIT

Efficacy and Tolerance of Cannabidiol in Patients with Severe Pruritus: a Multicenter, Double-blind, Randomized, Placebo-controlled Study

Pruritus is defined as an unpleasant sensation leading to the need to scratch. Medications for pruritus are much less effective than those used for pain and it is imperative to find new therapeutic options.
Over the last 20 years, the understanding of the pathophysiology of pruritus has progressed significantly, opening new possible therapeutic fields. Among these, cannabinoids seem very promising because the physiological inhibitory role of endocannabinoids, mainly produced by neurons, has been well demonstrated. Data from the literature suggest that the antipruritic effects of cannabinoids are due to a combination of effects on neuronal activation, transmission along the afferent pathway, and local modulation of keratinocytes and mast cells. The antipruritic effect is peripheral and central, through modulation of CB1, CB2 or TRPV1 channels. CB1 and CB2 receptors are specific cannabinoid receptors, CB1 being present at the central and peripheral level while CB2 is only peripheral and very present in the skin. Cannabinoids can also bind to TRPV1, and thus inhibit neurogenic inflammation by antagonizing or stabilizing this ion channel, which prevents neuronal activation by pruritogenic mediators. Phytocannabinoids are derived from cannabis and are used for a variety of purposes, with their development for medical purposes expanding rapidly. The two best known are tetrahydrocannabinol (THC) and cannabidiol (CBD). THC binds to TRPV1, CB2 and CB1, the activation of the latter being at the origin of parallel psychotropic effects. CBD binds mainly to TRPV1, which allows us to expect very favorable effects on pruritus, neurogenic inflammation and skin pain, without fearing side effects of this type.
A limited number of studies suggest that cannabinoids may be useful topically or systemically, in humans or animals, but no comparative study with placebo has been performed. These encouraging results have been observed in cases of induced pruritus, idiopathic pruritus, eczema, uremic pruritus, cholestatic pruritus, prurigo, sensitive skin or even epidermolysis bullosa.
Currently, the ANSM is conducting an evaluation of the effects of medical cannabis on severe pain. We propose to evaluate the effects on severe pruritus in a randomized placebo-controlled study one of the products chosen by the ANSM in this context, the oil LITTLE GREEN PHARMA, which we choose for its dominant CBD ratio (THC < 5 mg/ml, CBD > 5 mg/ml).

开始日期2025-01-01

申办/合作机构

University Hospital of Brest

NCT06177197 / Not yet recruitingN/AIIT

Bronchiolitis Clearance Airways with Seaserum : a Doubled Blind Randomized Study

The objective of this study is to show that the use of electrodialyzed seawater reduces the duration (in days) of symptoms in acute infant bronchiolitis compared with the use of saline solution in infants aged 1 month to less than one year.
B-CLASS study is a multicenter, prospective, controlled, randomized, double label blind.

开始日期2024-11-01

申办/合作机构

University Hospital of Brest

100 项与 University Hospital of Brest 相关的临床结果

登录后查看更多信息

0 项与 University Hospital of Brest 相关的专利（医药）

登录后查看更多信息

993

项与 University Hospital of Brest 相关的文献（医药）

2024-11-01·Journal of Thrombosis and Haemostasis

Fibrinolysis is impaired in patients with primary immune thrombocytopenia

Article

作者: Wolberg, Alisa S ; Rast, Jasmin ; de Moreuil, Claire ; Fillitz, Michael ; de Laat, Bas ; Reitsma, Stéphanie E ; Pabinger, Ingrid ; Wolberg, Alisa S. ; Reitsma, Stéphanie E. ; Gebhart, Johanna ; Quehenberger, Peter ; Schramm, Theresa ; Ay, Cihan ; Mehic, Dino

BACKGROUNDPatients with primary immune thrombocytopenia (ITP) have an increased risk of thrombosis, which may be due to altered fibrinolysis.OBJECTIVESTo elucidate the clinical impact of delayed fibrinolysis in ITP patients.METHODSA turbidimetric clot formation and lysis assay and a fluorometric plasmin generation (PG) assay were performed, and levels of plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA), tPA-PAI-1 complexes, α2-antiplasmin, thrombin activatable fibrinolysis inhibitor, and D-dimer were assessed in 86 adult primary ITP patients and 78 healthy controls (HCs).RESULTSITP patients showed significantly delayed clot formation, increased clot density, and prolonged clot lysis time (CLT) compared with HCs, with a median (IQR) CLT of 28.0 (13.7-34.7) minutes in patients and 17.3 (12.0-28.0) minutes in HCs, while in the PG assay, only the lag time was prolonged. In ITP patients compared with controls, PAI-1 was higher (1.2 [0.8-2.6] vs 1.1 [0.6-2.1] U/mL) and tPA antigen and activity were lower (tPA antigen: 2.6 [1.1-4.4] vs 3.7 [3.2-4.7] ng/mL; tPA activity ≤ 0 U/mL: 26% vs 7%). TPA-PAI-1 complex levels were positively associated with CLT in multiple linear regression analysis (β = 0.241; P = .019), whereas PG parameters were not associated with CLT. Six patients who developed thrombosis during follow-up had higher levels of tPA-PAI-1 complexes.CONCLUSIONProlonged CLT and delayed onset of PG may indicate a hypofibrinolytic tendency in ITP patients, as also indicated by high PAI-1 and low tPA levels. No association was found between fibrinolytic potential and the bleeding phenotype, whereas higher tPA-PAI-1 complex levels were associated with prolonged CLT and increased in patients with future thrombosis.

2024-11-01·The Journal of Molecular Diagnostics

Tailored Digital PCR Follow-Up of Rare Fusion Transcripts after Initial Detection through RNA Sequencing in Hematological Malignancies

Article

作者: Basinko, Audrey ; Jalaber, Elie ; Fest, Thierry ; Lachot, Sébastien ; de Tayrac, Marie ; Toujani, Saloua ; Luque Paz, Damien ; Marchand, Tony ; Houot, Roch ; Wiber, Margaux ; Pastoret, Cédric ; Cousin, Elie ; Voirin, Emeline ; Carras, Sylvain ; Desmares, Anne ; Lambert, Wayne-Corentin ; Boulland, Marie-Laure ; Aliouat, Amyra ; Lachot, Sebastien Sébastien ; Paz, Damien Luque

Minimal residual disease (MRD) monitoring plays a pivotal role in the management of hematologic malignancies. Well-established molecular targets, such as PML::RARA, CBFB::MYH11, or RUNX1::RUNX1T1, are conventionally tracked by quantitative RT-PCR. Recently, a broader landscape of fusion transcripts has been unveiled through transcriptomic analysis. These newly discovered fusion transcripts may emerge as novel molecular markers for MRD quantification. In this study, we compared a targeted RNA-sequencing (RNA-seq) approach (FusionPlex) with a whole-transcriptomic strategy (Advanta RNA-Seq XT) for fusion detection in a training set of 21 samples. We evidenced a concordance of 100% for the detection of known fusions, and showed a good correlation for gene expression quantification between the two techniques (Spearman r = 0.77). Additionally, we prospectively evaluated the identification of fusions by targeted RNA-seq in a real-life series of 126 patients with hematological malignancy. At least one fusion transcript was detected for 60 patients (48%). We designed tailored digital PCR assays for 11 rare fusions, and validated this technique for MRD quantification with a limit of detection of <0.01%. The combination of RNA-seq and tailored digital PCR may become a new standard for MRD evaluation in patients lacking conventional molecular targets.

2024-10-21·Journal of Investigational Allergy and Clinical Immunology

SQ HDM Sublingual Immunotherapy Tablet for the Treatment of HDM Allergic Rhinitis and Asthma Improves Subjective Sleepiness and Insomnia: An Exploratory Analysis of the Real-life CARIOCA Study

Article

作者: Chartier, A ; Jaffuel, D ; Demoly, P ; Leroyer, C ; Serrano, E

Background: Knowledge of the effectiveness of house dust mite (HDM) sublingual immunotherapy (SLIT) in allergic rhinitis (AR) and asthma-associated sleep disorders remains incomplete. A noninterventional study was conducted to assess the effect of the standardized quality (SQ) HDM SLIT tablet on safety and symptoms in adults with respiratory allergies caused by HDM. The study also assessed the status of insomnia and daytime sleepiness in patients with AR and/or asthma-associated sleep disorders treated with the SQ HDM SLIT tablet. Methods: This was a 12-month multicenter, longitudinal, and prospective study. Participants started the SQ HDM SLIT tablet for moderateto-severe HDM-induced AR that was persistent despite the use of symptom-relieving medication or HDM-induced asthma-associated sleep disorders that were not well controlled with inhaled corticosteroids and were associated with mild-to-severe HDM-induced AR. Sleep symptoms were measured using the Insomnia Severity Index (ISI) questionnaire and the Epworth Sleepiness Scale (ESS). Results: A total of 1526 adult patients were enrolled, and 1483 were eventually included in the analysis. At baseline, 41.5% of patients reported sleep disorders; of these, 77.0% had insomnia and 28.9% experienced excessive daytime sleepiness. Insomnia was significantly more frequent among patients with uncontrolled AR (83.1%) than among those with controlled AR (52.6%) (P<.0001). Over time, 48.3% and 59.7% of patients, respectively, reported an improvement greater than the minimal clinically important difference in the ISI and ESS scales. Conclusion: In patients with HDM-induced AR and/or asthma-associated sleep disorders, an improvement in subjective insomnia and sleepiness was observed after 1 year of treatment with the SQ HDM SLIT tablet in a real-life setting.

项与 University Hospital of Brest 相关的新闻（医药）

2023-04-14

·Healthcare Digital

3D printing technology for personalised healthcare

3D printing 3D printing technology is poised to transform the healthcare sector, says SkyQuest's 3D printing in healthcare market report From footwear to houses, chess pieces to teeth, there’s nothing 3D printing manufacturers will turn down. A recent report from SkyQuest anticipates major growth of 3D printing in healthcare, to reach a value of US$6.21bn by 2030. SkyQuest is a Research and Investment Bank and Accelerator of Technology, which provides access to technologies, markets and finance sectors. The company works with entrepreneurs and investors to utilise the economic potential of ideas. Recently, SkyQuest has had its eye on the impact of 3D printing technology. 3D printing in healthcare With 3D printing, healthcare professionals can build specific items immediately which fit uniquely to the patient’s body. Those in the profession are excited about the future. “Our view is that 3D printing has much to offer the healthcare industry,” said Ricky Wildman , Professor in Chemical Engineering at the University of Nottingham . “The number one, I suppose, for the healthcare industry is the fact that you can personalise so much in this and you can make it on demand and bespoke.” “Between saving operating time, developing personalised surgery and low-cost manufacturing, I see few limits to the use of 3D printing in hospitals,” said Samuel Guigo , a radio technician responsible for 3D printers at the University Hospital of Brest . “Like in the other many industries that use 3D printing, additive manufacturing is used for a variety of purposes in healthcare institutions. And in hospitals, the main use is probably the creation of surgical guides.” According to the SkyQuest, key factors propelling the 3D printing market expansion are: 3D printing technology improvements Customisation and personalisation Increased R&D investments The existence of a sizable patient pool An increase in biomedical applications 4D printing on the horizon for healthcare While 3D printing may be a futuristic concept to many - the idea of 4D printing has been around manufacturing circles for years. This process involves using 3D printing technology in the manufacturing of an item which can change its shape and behaviour - for example, when it comes into contact with a different element or temperature. Its very nature makes it perfect for use in healthcare - especially in replacement organs. As new research and development propels the industry forward, the 4D printing market is expected to reach US$1971mn by 2030. UK-based company 4D Biomaterials is excited about the potential 4D printing technology has for the healthcare sector and recently announced that it will launch its 4D Design medical device design and innovation services at Formnext . This includes a variety of services to assist medical device developers as they explore the use of biodegradable medical products using 4D Biomaterials’ 4Degra photocurable polycarbonate urethane polymer. “The combination of our material's unique properties and the design freedom provided by additive manufacturing really stimulated their imaginations, but they need specialist knowledge and technology access to translate these exciting concepts into viable devices,” explained Phil Smith , 4D Biomaterials CEO. “4D Design provides both expertise and practical solutions to enhance their creative processes."